Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
Nektar Therapeutics (NKTR) had Operating Cash Flow per Share of $-5.62 for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$9.39M |
|
$-55.65M |
|
-- |
|
$9.39M |
|
$67.19M |
|
$-57.80M |
|
$2.76M |
|
$-55.05M |
|
$-55.05M |
|
$-55.07M |
|
$-55.65M |
|
$-55.65M |
|
$-55.07M |
|
$-57.80M |
|
$-61.16M |
|
34.18M |
|
34.18M |
|
$-1.63 |
|
$-1.63 |
|
| Balance Sheet Financials | |
$679.33M |
|
-- |
|
$357.92M |
|
$1.04B |
|
$75.48M |
|
-- |
|
$112.05M |
|
$187.53M |
|
$849.72M |
|
$849.72M |
|
$849.72M |
|
34.21M |
|
| Cash Flow Statement Financials | |
$-192.00M |
|
$-683.00M |
|
$894.57M |
|
$15.12M |
|
$34.69M |
|
$19.57M |
|
$10.47M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-615.83% |
|
-615.83% |
|
-- |
|
-586.47% |
|
-592.91% |
|
$-192.51M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-6.55% |
|
-6.55% |
|
-5.37% |
|
-6.55% |
|
$24.84 |
|
$-5.63 |
|
|
Operating Cash Flow per Share |
$-5.62 |